142 related articles for article (PubMed ID: 9620551)
1. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation.
Houldsworth J; Xiao H; Murty VV; Chen W; Ray B; Reuter VE; Bosl GJ; Chaganti RS
Oncogene; 1998 May; 16(18):2345-9. PubMed ID: 9620551
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.
Rao PH; Houldsworth J; Palanisamy N; Murty VV; Reuter VE; Motzer RJ; Bosl GJ; Chaganti RS
Cancer Res; 1998 Oct; 58(19):4260-3. PubMed ID: 9766648
[TBL] [Abstract][Full Text] [Related]
3. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Mueller S; Schittenhelm M; Honecker F; Malenke E; Lauber K; Wesselborg S; Hartmann JT; Bokemeyer C; Mayer F
Int J Oncol; 2006 Aug; 29(2):471-9. PubMed ID: 16820891
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of treatment response in human germ cell tumors.
Mayer F; Stoop H; Scheffer GL; Scheper R; Oosterhuis JW; Looijenga LH; Bokemeyer C
Clin Cancer Res; 2003 Feb; 9(2):767-73. PubMed ID: 12576448
[TBL] [Abstract][Full Text] [Related]
5. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
6. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
7. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
8. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
[TBL] [Abstract][Full Text] [Related]
11. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
Duale N; Lindeman B; Komada M; Olsen AK; Andreassen A; Soderlund EJ; Brunborg G
Mol Cancer; 2007 Aug; 6():53. PubMed ID: 17711579
[TBL] [Abstract][Full Text] [Related]
12. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
Bagrodia A; Lee BH; Lee W; Cha EK; Sfakianos JP; Iyer G; Pietzak EJ; Gao SP; Zabor EC; Ostrovnaya I; Kaffenberger SD; Syed A; Arcila ME; Chaganti RS; Kundra R; Eng J; Hreiki J; Vacic V; Arora K; Oschwald DM; Berger MF; Bajorin DF; Bains MS; Schultz N; Reuter VE; Sheinfeld J; Bosl GJ; Al-Ahmadie HA; Solit DB; Feldman DR
J Clin Oncol; 2016 Nov; 34(33):4000-4007. PubMed ID: 27646943
[TBL] [Abstract][Full Text] [Related]
13. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
14. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
15. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
16. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
Asada N; Tsuchiya H; Tomita K
Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
[TBL] [Abstract][Full Text] [Related]
17. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides.
Datta K; Shah P; Srivastava T; Mathur SG; Chattopadhyay P; Sinha S
Cancer Gene Ther; 2004 Aug; 11(8):525-31. PubMed ID: 15167899
[TBL] [Abstract][Full Text] [Related]
18. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
19. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis.
Wen WH; Bernstein L; Lescallett J; Beazer-Barclay Y; Sullivan-Halley J; White M; Press MF
Cancer Res; 2000 May; 60(10):2716-22. PubMed ID: 10825146
[TBL] [Abstract][Full Text] [Related]
20. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
